Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma

Area of Science:

• Oncology
• Pharmacology

Background:

• Relapsed and refractory multiple myeloma (RRMM) poses a significant therapeutic challenge due to acquired drug resistance.
• Histone deacetylase inhibitors (HDACi) represent a class of drugs with potential to overcome this resistance.

Purpose of the Study:

• To provide a comprehensive review of preclinical and clinical studies on panobinostat for multiple myeloma treatment.
• To evaluate the efficacy of panobinostat in resensitizing myeloma cells and its synergistic effects with other agents.

Main Methods:

• Review of preclinical research investigating panobinostat's mechanism of action and cellular effects.
• Analysis of clinical trial data assessing panobinostat in patients with RRMM.
• Examination of studies evaluating drug combinations involving panobinostat.

Main Results:

• Panobinostat, an oral HDACi, has shown efficacy in resensitizing refractory multiple myeloma cells in preclinical and clinical settings.
• Synergistic activity of panobinostat has been observed when combined with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
• Panobinostat demonstrates a multi-pathway cellular effect relevant to overcoming drug resistance.

Conclusions:

• Panobinostat is a promising HDAC inhibitor for the treatment of relapsed and refractory multiple myeloma.
• Its ability to resensitize resistant cells and synergize with other therapies supports its role in managing advanced multiple myeloma.
• Further clinical investigation supports panobinostat as a valuable therapeutic option.